PL1814843T3 - (2R)-enancjomer chlorku DOTAP - Google Patents

(2R)-enancjomer chlorku DOTAP

Info

Publication number
PL1814843T3
PL1814843T3 PL05802304T PL05802304T PL1814843T3 PL 1814843 T3 PL1814843 T3 PL 1814843T3 PL 05802304 T PL05802304 T PL 05802304T PL 05802304 T PL05802304 T PL 05802304T PL 1814843 T3 PL1814843 T3 PL 1814843T3
Authority
PL
Poland
Prior art keywords
dotap
enantiomer
chloride
Prior art date
Application number
PL05802304T
Other languages
English (en)
Inventor
Michael Platscher
Alfred Hedinger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL1814843T3 publication Critical patent/PL1814843T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05802304T 2004-11-26 2005-11-07 (2R)-enancjomer chlorku DOTAP PL1814843T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
EP05802304.5A EP1814843B1 (de) 2004-11-26 2005-11-07 (2r)-enantiomer von dotap-chlorid
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid

Publications (1)

Publication Number Publication Date
PL1814843T3 true PL1814843T3 (pl) 2015-11-30

Family

ID=35789283

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05802304T PL1814843T3 (pl) 2004-11-26 2005-11-07 (2R)-enancjomer chlorku DOTAP

Country Status (20)

Country Link
US (2) US8853283B2 (pl)
EP (1) EP1814843B1 (pl)
JP (1) JP4880612B2 (pl)
KR (1) KR101249370B1 (pl)
CN (2) CN101065350A (pl)
AU (1) AU2005309107B2 (pl)
BR (2) BRPI0518489B8 (pl)
CA (1) CA2589218C (pl)
DE (1) DE102004057303A1 (pl)
ES (1) ES2545906T3 (pl)
HU (1) HUE027554T2 (pl)
IL (1) IL183324A (pl)
MX (1) MX2007006128A (pl)
NO (1) NO338885B1 (pl)
NZ (2) NZ556060A (pl)
PL (1) PL1814843T3 (pl)
PT (1) PT1814843E (pl)
RU (1) RU2463291C2 (pl)
WO (1) WO2006056312A1 (pl)
ZA (1) ZA200705169B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
TR201906107T4 (tr) 2011-05-20 2019-05-21 Merck Patent Gmbh Dotap klorürün stabil kristal modifikasyonlarının hazırlanması.
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
CN110075292A (zh) * 2011-09-12 2019-08-02 Pds生物科技公司 微粒疫苗制剂
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Pds生技公司 改良之疫苗組成物及使用方法
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7280624B2 (ja) * 2017-04-03 2023-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル(dnv)
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
AU710170B2 (en) * 1996-05-08 1999-09-16 Nika Health Products Limited Cationic virosomes as transfer system for genetic material
ATE395904T1 (de) * 1996-09-13 2008-06-15 Lipoxen Technologies Ltd Liposome
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) * 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) * 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
EP1814843B1 (de) 2015-06-24
PT1814843E (pt) 2015-10-13
ES2545906T3 (es) 2015-09-16
BRPI0518489B8 (pt) 2021-05-25
MX2007006128A (es) 2007-07-13
US20140370081A1 (en) 2014-12-18
AU2005309107A1 (en) 2006-06-01
CN102796016A (zh) 2012-11-28
US20080014254A1 (en) 2008-01-17
JP2008521757A (ja) 2008-06-26
NZ556060A (en) 2010-03-26
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
IL183324A (en) 2013-10-31
EP1814843A1 (de) 2007-08-08
DE102004057303A1 (de) 2006-06-01
BR122019018186B1 (pt) 2021-03-09
CN102796016B (zh) 2015-09-02
US9457087B2 (en) 2016-10-04
AU2005309107B2 (en) 2011-07-21
US8853283B2 (en) 2014-10-07
RU2007123673A (ru) 2009-01-10
KR101249370B1 (ko) 2013-04-01
NO20073286L (no) 2007-06-25
JP4880612B2 (ja) 2012-02-22
CA2589218A1 (en) 2006-06-01
CA2589218C (en) 2013-12-17
BRPI0518489A2 (pt) 2008-11-25
HUE027554T2 (en) 2016-10-28
NZ582382A (en) 2010-08-27
BRPI0518489B1 (pt) 2020-03-31
ZA200705169B (en) 2008-08-27
IL183324A0 (en) 2007-09-20
HK1178143A1 (zh) 2013-09-06
KR20070084501A (ko) 2007-08-24
WO2006056312A1 (de) 2006-06-01
CN101065350A (zh) 2007-10-31
BR122019018186B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
PT1814843E (pt) (2r)-enantiómero de cloreto de dotap
PT1778618E (pt) Síntese de trietilenotetraminas
EP1809137A4 (en) ASYMMETRICAL UMBRELLA
TWI350744B (en) Inter-labial pad
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
ZA200706093B (en) Reducing by-catch of seabirds
PL1763520T3 (pl) Zastosowanie tripodstawionych benzopiranonów
EP1711484A4 (en) SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES
ZA200701527B (en) Composition comprising statin
EP1833808A4 (en) NEW BENZOTHIAZOLSULFONIC ACID AMIDE
AU158365S (en) Set of fins for surfcraft
GB0418756D0 (en) Supports
DE602005024518D1 (en) C10-cyclopentylester-substituierte taxane
GB0403729D0 (en) Pad
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
GB0519100D0 (en) Scented pad
GB0410323D0 (en) Sex aid
IL178683A0 (en) Methods of diminishing co-abuse potenitial
GB2416051B (en) Selection of component
GB0411026D0 (en) Concept fifteen
ZA200508325B (en) Manufacture of kerbstones
GB0421059D0 (en) Concept thirteen
GB0412138D0 (en) Definition of zeroclick
HU0400952D0 (en) Treatment of anus-cancer
GB0426033D0 (en) Priority pad